GNF-7 - Bcr-Abl 抑制剂 - 生命科学试剂 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEGNF-7Cat. No.: HY-10943CAS No.: 839706-07-9分式: CHFNO分量: 547.53作靶点: Bcr-Abl作通路: Protein Tyrosine Kinase/RTK储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 33 mg/mL (60.27 mM)* means soluble,

2、 but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 1.8264 mL 9.1319 mL 18.2638 mL5 mM 0.3653 mL 1.8264 mL 3.6528 mL10 mM 0.1826 mL 0.9132 mL 1.8264 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验 请根据您的实验动物和给药式选择适当的溶解案，配制前请先配制澄清的储备液，再依次添加助溶剂(为保证实验结果的可靠性，体内实验的作液，建议您现现配，当天使；澄

3、清的储备液可以根据储存条件，适当保存；以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2 mg/mL (3.65 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2 mg/mL (3.65 mM); Clear solution1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEBIOLOGICAL

4、 ACTIVITY物活性 GNF-7 抑制 Bcr-Abl WT 和 Bcr-Abl T315I, IC50 分别为133 nM 和 61 nM。REFERENCES1. Choi HG, et al. A type-II kinase inhibitor capable of inhibiting the T315I gatekeeper mutant of Bcr-Abl. J Med Chem. 2010 Aug12;53(15):5439-48.2. Lu X, et al. Hybrid pyrimidine alkynyls inhibit the clinically resis

5、tance related Bcr-Abl(T315I) mutant. Bioorg Med Chem Lett. 2015 Sep1;25(17):3458-63.3. Liang X, et al. Discovery of 2-(3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitorfor ChMcePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792; 0